On October 18, the new anti-tumor drug "Recombinant L-IFN Adenovirus Injection" developed by Shanghai Yuansong Biotechnology Co., Ltd., an enterprise in the Industrial Comprehensive Development Zone, was approved by the Ethics Committee of the South Branch of the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University (Shanghai Fengxian District Central Hospital) to carry out clinical research approval initiated by researchers and enter clinical research.
"Recombinant L-IFN Adenovirus Injection" is developed based on the "Targeted Gene-Virus Therapy for Cancer" strategy, using a replicant human type 5 adenovirus with dual tumor targeting regulation as a vector, and carries an optimized interferon-like recombinant immune anti-cancer gene (L-IFN). This targeted viral drug can specifically replicate in tumor cells, targeting lysis of tumor cells without significant toxicity to normal cells. The anti-cancer genes carried by it can be copied in tumor cells with the viral vector in large quantities, and at the same time, a large number of L-IFN anti-cancer proteins are expressed and secreted in tumor cells, which not only has a direct killing effect on tumor cells, but more importantly, can stimulate the immune system to play an immunomodulatory role, thus playing a dual anti-tumor effect.
Preclinical research data show that "recombinant L-IFN adenovirus injection" has excellent safety and extremely exciting anti-cancer efficacy in a variety of transplant tumor models, such as lung cancer, bladder cancer, breast cancer, head and neck cancer, ovarian cancer, cervical cancer, melanoma, glioma, etc., with significant druggability and clinical translational value.